A B S T R A C T Immunocompetence was followed serially for 1 yr from the onset of treatment in 55 adult patients with acute leukemia. The tests used were delayed hypersensitivity responses to a battery of five recall antigens (dermatophytin, dermatophytin 0, candida, streptokinase-streptodornase, and mumps) and in vitro lymphocyte blastogenic responses to phytohemagglutinin and streptolysin 0. There was a strong correlation between immunocompetence at the start of treatment and a good prognosis; 32/39 patients who subsequently entered remission were initially immunocompetent compared to 4/15 who failed to enter remission.
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In the complete remission group there was a decline in competence starting from 2 to 5 mo after the onset of treatment. In those who remained in remission for 1 yr, competence recovered at 6 mo and remained vigorous thereafter. In those who relapsed before 1 yr, the decline in competence occurred 1 mo before relapse and competence continued to decline progressively during the 1 yr follow-up period. These studies suggest that therapeutic approaches which restore immunocompetence or prevent its decline will improve both the remission rate and the remission duration of patients with acute leukemia.
INTRODUCTION
Immunological surveillance has been established as an important mechanism in the etiology and pathogenesis of experimental cancer and is probably also implicated in the natural defense against cancer in man (1). During the last several years, a number of investigators have established that the immunocompetence of the cancer patient is directly related to a better prognosis. This has been demonstrated in Hodgkin's disease (2) , carcinoma of the lung (3), squamous cell carcinoma (4) , and malignant melanoma and other solid tumors (5) , to name a few.
We have previously demonstrated this phenomenon in patients with solid tumors using both in vivo delayed hypersensitivity responses to recall antigens, and in vitro lymphocyte blastogenic responses to mitogens and antigens (6) . In a study in 25 patients with acute leukemia (7) , we demonstrated that vigorous reactivity to recall antigens, the development of vigorous reactivity to a primary antigen, and in vitro lymphocyte blastogenic responses to mitogens and antigens, could be used to identify at the outset of treatment, those patients who subsequently had a good prognosis as a result of chemotherapy.
In the current study we have extended these observations to a group of 55 patients with acute leukemia. Patients were studied initially and then followed serially for approximately 1 yr. In addition to confirming the previously demonstrated correlation between vigorous immunocompetence and good prognosis, we have demonstrated that a decline in immunocompetence precedes frank relapse of this disease. The data generated in this study provide a rational basis for nonspecific immunotherapy of acute leukemia. It suggests that the addition of immunotherapy early in the chemical treatment of patients with acute leukemia could be highly effective in improving the response rate. Its continuation during remission could prolong remission duration. Ci/mM) was added and the blastogenic response of the stimulated and unstimulated lymphocytes was measured by
METHODS
[3H]thymidine incorporation. Results were reported as either net counts per minute (cpm) or the stimulation index (SI). The net cpm was the cpm in the stimulated culture minus the cpm in the control, and the SI was the cpm in the stimulated culture divided by the cpm in the control.
Data were analyzed mainly by the chi-square test using the 2 X 2 contingency table. The calculation was done using a program written for the Wang series 600 computer (Wang Laboratories, Tewksbury, Mass.), which yielded approximate P values as follows: P: 0.05 = 0.05 > < 0.025, P: 0.025 = 0.025 > < 0.01, P: 0.01 = 0.01 >< 0.005, P: 0.005 = 0.005 > < 0.001. Selected data were also analyzed by the Wilcoxon-signed rank test. Median values are used frequently in the tabulation of the data. Unless otherwise indicated these are medians of the median value of the five skin tests for each patient. Thus, for example, the value for the 33 complete remission patients reported in Table I is a median of 33 medians of five skin tests. Similarly, means for each group were the means of the mean of the five values.
RESULTS
The results of the first battery of delayed hypersensitivity skin tests with recall antigens, done between the first and second courses of chemotherapy for remission induction, are shown in Table I . Patients who subsequently entered complete remission showed vigorous delayed hypersensitivity and only 21% had a median skin test diameter (of the five skin tests) of zero. In contrast, patients who subsequently failed to enter remission had very poor reactivity and 73% had a median skin test diameter of zero. This difference was highly significant. Because of the small number of patients in the partial remission group, they did not differ significantly from the other two groups. Of interest, of the 7 patients in the complete remission group who had a median skin test diameter of zero, only 1 remained in remission at 1 yr; whereas of the 26 who had a median diameter greater than zero, 11 remained in remission at 1 yr. The median and mean values did not differ significantly.
This difference was also clearly demonstrable when the number of positive skin tests per patient was examined (Table II) . 28 out of 33 patients who subsequently This decline in immunocompetence in the complete remission patients is analyzed in detail in Table IV. By 2-3 mo after the start of chemotherapy, there was a dramatic increase in the percent of subjects whose median skin test diameter was zero. This increase in inmunoincompetence from 21 to 64% was highly significant.
The same phenomena were observed in the partial remission group. There was an initial improvement in skin test reactivity during the first mo of the study (from 33% with a median skin test diameter of zero to none) and subsequently there was a steady increase in the percent of subjects who were immunoincompetent (86% with a median skin test diameter of zero at 1 yr). By 6-7 mo after the start of chemotherapy, one-half of The two subgroups within the complete remission group were also compared. Significant findings were made only during the last evaluation period. In those patients whose remission lasted less than 12 mo, both the PHA and SLO responses were lower than those whose remission lasted greater than 12 mo. The SLO responses in these two groups were significantly different (30,500 vs. 9,800 cpm and 49.5 vs. 15 SI).
These data were also analyzed for the possible effects of factors known to influence the prognosis of patients with acute leukemia. These include the age of the pa- tients, the type of leukemia, and the history of prior therapy. The findings in this study could not be explained on the basis of any of these factors (Tables IX   and X) .
For example, although the majority of the failure group were AML patients, the correlation between immunocompetence and prognosis was seen in both AML and ALL. Thus (Table X) , among the AML patients who entered complete remission the median skin test diameter was 8 mm compared to 0 mm in the AML failures. Only 19% of the AML complete remission patients had a median skin test of zero compared to 69% of the AML failure patients. The same differences were seen in ALL. DISCUSSION The findings in this study confirm and extend our previous observations (7) . Thus, in patients with acute leukemia, immunocompetence relates to a good prognosis while immunoincompetence relates to a poor prognosis. The data in this study are particularly striking with regard to delayed hypersensitivity responses to recall antigens and are less striking but show this same trend in regard to in vitro lymphocyte blastogenic responses. This is the first study in which we are aware that serial studies of immunocompetence have been carried from the onset and during the course of intensive intermittent chemotherapy in patients with acute leukemia.
Although patients who initially had positive delayed hypersensitivity skin test reactivity entered complete or partial remission, both the complete and partial remission groups had a gradual but highly significant decline in this immunological reactivity in subsequent months. On more detailed analysis of the data, this decline in reactivity was shown to be much more pronounced among those patients who had entered remission but relapsed subsequently. The decline occurred or was detectable during the month before relapse. Thus, an immunocompetent patient with acute leukemia in complete remission, who loses his immunocompetence, is in danger of relapse. In contrast, the patients who entered remission and stayed in remission 1 yr or longer maintained their immunocompetence although it went through a transient decline. This decline occurred during the 2nd through the 5th mo of treatment, and was followed by partial recovery. This was the period when remission induction and consolidation therapy was most intensive and presumably the immunodepression was the result of chemotherapy. It can be assumed that the immune system in this group is vigorous enough to recover from the suppressive effects of chemotherapy whereas in the group which eventually relapses it is not. The fact that the latter group were immunocompetent initially when they had a tumor burden, but became incompetent before relapse, also suggests that their decline in immunocompetence is the result of chemotherapy acting on a susceptible immune system and not an immunosuppressive effect of the tumor burden.
Another interesting feature of these studies was the improvement in skin test reactivity between the first and second studies done during the 1st mo of treatment. method for lymphocyte cultures was described which the authors felt more accurately reflects the lymphoid organ and its overall response to mitogens (10) . On the other hand, the majority of studies using methods similar to ours in cancer patients have yielded useful data and similar clinical correlations (11, 12) . Several important conclusions can be drawn from these observations. They can be put into a general scheme concerning the relationship between the immunocompetence and the prognosis of the cancer patient. First, it appeared that individuals vary in their level of immunocompetence. Those who are more immunocompetent in spite of their immunosuppressive tumor burden (and any residual effects of prior therapy) have a greater probability of entering remission than those who are less immunocompetent. Furthermore, the chemotherapy that the patients receive is immunosuppressive. However, the ability to recover from this immunosuppression is associated with prolonged remission, whereas the failure to develop or to recover is competence after this suppression is associated with a short remission. Thus the complex relationship of immunocompetence to prognosis in leukemia can be explained. The leukemia (tumor-burden) innate (presumably genetic and age-related) defects in immune status, and immunosuppressive therapy each play a role. We feel that no single factor can adequately explain the immunological-clinical correlations described in this paper.
These observations form a rational basis for the development of nonspecific active immunotherapy for leukemia. This should be applied early during remission induction to improve the immunocompetence of those incompetent patients who would not normally enter remission. The hope would be that they would become competent and would enter remission. Nonspecific active immunotherapy should also be given during remission maintenance to delay or prevent the decline in immunocompetence which is associated with the relapse in these patients. Indeed, nonspecific active immunotherapy (combined with active specific immunotherapy) has been shown to prolong complete remission in acute leukemia (13, 14) .
One might also consider which component of the immune system is predominantly involved in the immunological deficiency observed in these patients. Defects in delayed hypersensitivity represent either a macrophage (15) or a T-lymphocyte (16) defect. Both are suppressed by chemotherapy (17) and malignancy (18) .
Humoral immunity is important in host defense against leukemia (19) and our observation that SLO responses in these patients were more suppressed than PHA responses suggests that a B-lymphocyte defect was also present.
Many studies of various types of cancer patients confirm and are extended by the observations in this paper.
A relationship between a good prognosis and a high level of immunocompetence has been observed in Hodgkin's disease (2) , malignant melanoma and other solid tumors (5), head and neck cancer (4) , lung cancer (3) , and in acute leukemia (7) . Prolonged chemotherapy in acute leukemia of childhood is associated with severe immunological incompetence which gradually recovers after the chemotherapy is stopped (20) 
